Skip to main content

Table 2 Laboratory investigations, abdominal ultrasound, and liver stiffness measurements in both HCV patients post chemotherapy (cases) and HCV patients without cancer (controls)

From: Efficacy and safety of direct-acting antivirals for HCV in patients with extrahepatic malignancies: real-life experience

  HCV patients post chemotherapy
Mean ± SD
HCV patients without cancer
Mean ± SD
p-value
ALT (IU/L) 58.6 ± 37.36 58.7 ± 102.6 0.993
AST (IU/L) 59.6 ± 31.8 54.2 ± 55.6 0.440
Baseline HCV RNA × log 10 5.63 ± 0.91 5.54 ± 0.95 0.63
AFP (U/L) 10.8 ± 16.86 9.7 ± 15.13 0.712
Albumin (g/dl) 4.02 ± 0.65 3.99 ± 0.90 0.76
Total bilirubin (mg/dl) 0.80 ± 0.40 1.06 ± 1.17 0.048
Indirect bilirubin (mg/dl) 0.51 ± 0.42 0.50 ± 0.28 0.98
TSH 2.23 ± 1.8 1.74 ± 1.08 0.15
WBC × 103 mm3 6.04 ± 3.98 7.13 ± 10.46 0.37
ANC × 103 mm3 4.07 ± 8.21 6.51 ± 12.23 0.23
Hb (g/l) 13.22 ± 1.85 12.94 ± 1.50 0.27
Platelets × 103 mm3 173.8 ± 71.8 184.83 ± 82.4 0.35
PC% 84.81 ± 16.36 86.37 ± 10.52 0.537
INR 1.12 ± 0.16 1.10 ± 0.13 0.38
Creatinine (mg/dl) 0.86 ± 0.26 0.91 ± 0.79 0.54
Glucose (mg/dl) 107.15 ± 31.66 109.52 ± 30.73 0.66
HbA1C% 6.34 ± 1.09 7.32 ± 1.46 0.013
Liver ultrasound known cirrhotic N (%)
17 (20.5%)
N (%)
12 (13.6%)
Total
29 (17%)
0.233
Liver stiffness (Kpa) 15.28 ± 8.12 23.78 ± 16.77 0.28
FIB-4 calculation 3.14 ± 2.47 2.95 ± 3.06 0.655
  1. p ≤ 0.05 is significant